First AD

Second AD

Unmet Needs and Future Perspectives of RET-Positive NSCLC

 Thank you to Dr Sands for this insightful discussion. Before we end, I would like to get some closing thoughts from Dr Sands on unmet needs and future perspectives on the treatment of 

Video Series

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

My Treatment Approach: My Treatment Approach: Navigating Genetic Testing and RET-Targeted Treatments in NSCLC 

Panelists discuss the unmet needs and future perspectives in the treatment of RET-positive non–small cell lung cancer (NSCLC), focusing on areas for improvement in therapy and the potential for new treatment strategies.

Patient Case: 67 Year-Old Male With Stage IIIB+ NSCLC Awaiting for Mutation Testing

Next Steps to Stage IIIB NSCLC Patient Case Awaiting Molecular Testing and Usability of Liquid Biopsy

Testing Methodologies and Standards in Metastatic NSCLC

Practical Considerations in Metastatic NSCLC: Access and Timing of Testing

Clinical-Decision Making: When to Treat Advanced NSCLC Without Mutational Results

Initial Approach to Management of RET-Positive NSCLC

Patient and Therapy Considerations Guiding Initiation of Treatment in RET-Positive NSCLC

Considerations for First-Line Targeted Therapies in Metastatic RET-Positive NSCLC

Role of Immunotherapy and Chemotherapy in RET-Positive NSCLC

Managing RET Inhibitor Treatment-Related Adverse Events

Monitoring Patients With RET-Positive NSCLC